Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 89

1.

A longitudinal FDG-PET study of transgenic mice overexpressing GSK- 3β in the brain.

de Cristóbal J, Garcia-Garcia L, Delgado M, Pozo MA, Medina M.

Curr Alzheimer Res. 2014 Feb;11(2):175-81.

PMID:
23905999
[PubMed - indexed for MEDLINE]
2.

Full reversal of Alzheimer's disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3.

Engel T, Hernández F, Avila J, Lucas JJ.

J Neurosci. 2006 May 10;26(19):5083-90.

PMID:
16687499
[PubMed - indexed for MEDLINE]
Free Article
3.

Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert.

Engel T, Goñi-Oliver P, Lucas JJ, Avila J, Hernández F.

J Neurochem. 2006 Dec;99(6):1445-55. Epub 2006 Oct 24.

PMID:
17059563
[PubMed - indexed for MEDLINE]
4.

Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments.

Hernández F, Borrell J, Guaza C, Avila J, Lucas JJ.

J Neurochem. 2002 Dec;83(6):1529-33.

PMID:
12472906
[PubMed - indexed for MEDLINE]
5.

Development of glucose intolerance in male transgenic mice overexpressing human glycogen synthase kinase-3beta on a muscle-specific promoter.

Pearce NJ, Arch JR, Clapham JC, Coghlan MP, Corcoran SL, Lister CA, Llano A, Moore GB, Murphy GJ, Smith SA, Taylor CM, Yates JW, Morrison AD, Harper AJ, Roxbee-Cox L, Abuin A, Wargent E, Holder JC.

Metabolism. 2004 Oct;53(10):1322-30.

PMID:
15375789
[PubMed - indexed for MEDLINE]
6.

Transgenic mice overexpressing glycogen synthase kinase 3beta: a putative model of hyperactivity and mania.

Prickaerts J, Moechars D, Cryns K, Lenaerts I, van Craenendonck H, Goris I, Daneels G, Bouwknecht JA, Steckler T.

J Neurosci. 2006 Aug 30;26(35):9022-9.

PMID:
16943560
[PubMed - indexed for MEDLINE]
Free Article
8.

Longitudinal assessment of a transgenic animal model of tauopathy by FDG-PET imaging.

de Cristóbal J, García-García L, Delgado M, Pérez M, Pozo MA, Medina M.

J Alzheimers Dis. 2014;40 Suppl 1:S79-89. doi: 10.3233/JAD-132276.

PMID:
24577468
[PubMed - in process]
9.

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice.

Lucas JJ, Hernández F, Gómez-Ramos P, Morán MA, Hen R, Avila J.

EMBO J. 2001 Jan 15;20(1-2):27-39.

PMID:
11226152
[PubMed - indexed for MEDLINE]
Free PMC Article
10.

Tau phosphorylation in transgenic mice expressing glycogen synthase kinase-3beta transgenes.

Brownlees J, Irving NG, Brion JP, Gibb BJ, Wagner U, Woodgett J, Miller CC.

Neuroreport. 1997 Oct 20;8(15):3251-5.

PMID:
9351652
[PubMed - indexed for MEDLINE]
11.

Disruption of glycogen synthase kinase-3-beta activity leads to abnormalities in physiological measures in mice.

Ahnaou A, Drinkenburg WH.

Behav Brain Res. 2011 Aug 1;221(1):246-52. doi: 10.1016/j.bbr.2011.03.004. Epub 2011 Mar 8.

PMID:
21392539
[PubMed - indexed for MEDLINE]
12.

Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation.

Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J.

Br J Pharmacol. 2007 Nov;152(6):959-79. Epub 2007 Oct 1.

PMID:
17906685
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Quantitative longitudinal interrelationships between brain metabolism and amyloid deposition during a 2-year follow-up in patients with early Alzheimer's disease.

Förster S, Yousefi BH, Wester HJ, Klupp E, Rominger A, Förstl H, Kurz A, Grimmer T, Drzezga A.

Eur J Nucl Med Mol Imaging. 2012 Dec;39(12):1927-36. doi: 10.1007/s00259-012-2230-9. Epub 2012 Aug 28.

PMID:
22926714
[PubMed - indexed for MEDLINE]
14.

Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β).

Cole EL, Shao X, Sherman P, Quesada C, Fawaz MV, Desmond TJ, Scott PJ.

Nucl Med Biol. 2014 Jul;41(6):507-12. doi: 10.1016/j.nucmedbio.2014.03.025. Epub 2014 Apr 2.

PMID:
24768148
[PubMed - in process]
15.

The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice.

Ahn SW, Kim JE, Park KS, Choi WJ, Hong YH, Kim SM, Kim SH, Lee KW, Sung JJ.

J Neurol Sci. 2012 Sep 15;320(1-2):1-5. doi: 10.1016/j.jns.2012.05.038. Epub 2012 Jun 12.

PMID:
22698482
[PubMed - indexed for MEDLINE]
16.

Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease.

Farr SA, Ripley JL, Sultana R, Zhang Z, Niehoff ML, Platt TL, Murphy MP, Morley JE, Kumar V, Butterfield DA.

Free Radic Biol Med. 2014 Feb;67:387-95. doi: 10.1016/j.freeradbiomed.2013.11.014. Epub 2013 Dec 16.

PMID:
24355211
[PubMed - in process]
17.

Lithium-mediated phosphorylation of glycogen synthase kinase-3beta involves PI3 kinase-dependent activation of protein kinase C-alpha.

Kirshenboim N, Plotkin B, Shlomo SB, Kaidanovich-Beilin O, Eldar-Finkelman H.

J Mol Neurosci. 2004;24(2):237-45.

PMID:
15456937
[PubMed - indexed for MEDLINE]
18.
19.

GSK-3beta and oxidative stress in aged brain. Role of poly(ADP- -ribose) polymerase-1.

Songin M, Jeśko H, Czapski G, Adamczyk A, Strosznajder RP.

Folia Neuropathol. 2007;45(4):220-9.

PMID:
18176896
[PubMed - indexed for MEDLINE]
20.

Inhibition of glycogen synthase kinase 3 beta attenuates neurocognitive dysfunction resulting from cranial irradiation.

Thotala DK, Hallahan DE, Yazlovitskaya EM.

Cancer Res. 2008 Jul 15;68(14):5859-68. doi: 10.1158/0008-5472.CAN-07-6327. Erratum in: Cancer Res. 2008 Oct 1;68(19):8189.

PMID:
18632640
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk